Patents by Inventor Xiaobin Ge

Xiaobin Ge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NLRP3 inflammasome inhibitors
    Patent number: 12378222
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: October 16, 2024
    Date of Patent: August 5, 2025
    Assignee: Novartis AG
    Inventors: Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20250034114
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: October 16, 2024
    Publication date: January 30, 2025
    Inventors: Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20240067627
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R1, R2, R3, R4 and R5 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: August 1, 2023
    Publication date: February 29, 2024
    Inventors: Xiaobin Ge, Henri Mattes, Zhicong Shi, Mei Xia, Ning Ye